Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate-Reference-Cited by-同舟云学术

Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate

Published:2015-05-20 Issue:11 Volume:26 Page:2216-2222
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Lim Reyna K. V.¹,Yu Shan¹,Cheng Bo¹,Li Sijia¹,Kim Nam-Jung²,Cao Yu²,Chi Victor¹,Kim Ji Young¹,Chatterjee Arnab K.¹,Schultz Peter G.¹²,Tremblay Matthew S.¹,Kazane Stephanie A.¹

Affiliation:

1. California Institute for Biomedical Research (Calibr), 11119 North Torrey Pines Road, La Jolla, California 92037, United States

2. Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

Funder

California Institute for Biomedical Research

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.5b00203

Reference44 articles.

1. Potent antibody drug conjugates for cancer therapy

2. Antibody-Drug Conjugates in Cancer Therapy